GSK3 beta Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of GSK3 beta on different lysates using anti-GSK3 beta antibody at 1/1,000 dilution.
Lane 1: Hela
Lane 2: 293
Lane 3: NIH/3T3
Lane 4: PC12
Fig2: ICC staining GSK3 beta in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: ICC staining GSK3 beta in PC-3M cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Host Species; Species ReactivityRabbit; Human, Mouse
Application SummaryWB, ICC/IF, IHC, FC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesGlycogen synthase kinase-3 beta, Serine/threonine-protein kinase GSK3B
BackgroundGlycogen synthase kinase 3, or GSK-3, is a serine/threonine, proline-directed kinase involved in a diverse array of signaling pathways, including glycogen synthesis and cellular adhesion, and has been implicated in Alzheimer’s disease. Two forms of GSK-3, designated GSK-3α and GSK-3β, have been identified and differ in their subcellular localization. Tau, a microtubule-binding protein which serves to stabilize microtubules in growing axons, is found to be hyper-phosphorylated in paired helical filaments (PHF), the major fibrous component of neurofibrillary lesions associated with Alzheimer’s disease. Hyperphosphorylation of Tau is thought to be the critical event leading to the assembly of PHF. Six Tau protein isoforms have been identified, all of which are phosphorylated by GSK-3. This presents the possibility that miscues in GSK-3 signaling contribute to the onset of Alzheimer’s disease.(ET1607-71)